In Brief: Meridian Medical Technologies
This article was originally published in The Gray Sheet
Executive Summary
Meridian Medical Technologies: Initiates voluntary recall of 30,000 EpiEZPen auto epinephrine-injectors for treatment of allergic reactions Sept. 22 after receiving reports that six of the devices automatically deployed, making them ineffective in an emergency. No consumers were harmed in the incidents. Less than 4% of pens currently on shelves are involved in the Class I, nationwide recall -- which is limited to lot 6SA145, distributed by Dey Laboratories after July 30, 1996, the Columbia, Maryland firm says...
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.